Foundation Medicine (FMI) : During the past 4 weeks, traders have been relatively bearish on Foundation Medicine (FMI), hence the stock is down -11.07% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -11.95% relative to the S&P 500. The 4-week change in the price of the stock is -11.25% and the stock has fallen -12.53% in the past 1 week.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 13.06% and the fifty day Moving Average is 5.89%. Foundation Medicine, Inc. is up 12.11% in the last three month period. Year-to-Date the stock performance stands at -1.52%.
Foundation Medicine (NASDAQ:FMI): On Fridays trading session , Opening price of the stock was $20.77 with an intraday high of $21.37. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $20.31. However, the stock managed to close at $20.74, a loss of 0.10% for the day. On the previous day, the stock had closed at $20.76. The total traded volume of the day was 176,204 shares.
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patients individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products, FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and various sarcomas and pediatric cancers, are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.